Announcement of TTY Biopharm's unaudited income information in May 2024

2024.6.11

Provided by: TTY BIOPHARM COMPANY LIMITED
SEQ_NO 1 Date of announcement 2024/06/11 Time of announcement 16:29:55
Subject Announcement of TTY Biopharm's unaudited income information in May 2024
Date of events 2024/06/11 To which item it meets paragraph 53
Statement 1.Date of occurrence of the event:2024/06/11
2.Company name:TTY Biopharm Co., Ltd.
3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:TTY Biopharm posted a consolidated net sales of $444,210 thousands (expressed in NT dollars; unaudited), a consolidated operating profit of $108,406 thousands, and a consolidated income before tax of $130,999 thousands in May 2024; net income attributed to stockholders of the company was $96,635 thousands; EPS is $0.39.
Year-to-date consolidated net sales was $2,174,521 thousands (in NTdollars; unaudited), a consolidated operating profit was $461,297 thousands, and consolidated income before tax was $566,214 thousands until May 2024; year-to-date net income attributed to stockholders of the company was $425,206 thousands; EPS is $1.71.
6.Countermeasures:None.
7.Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):
The numbers above are unaudited. In term of the final net sales and profits, quarterly financial reports audited by independent accountants will prevail.
TOP